Bio­haven earns pre­ven­ta­tive nod for mi­graine med Nurtec, snar­ing a much-need­ed leg up over Ab­b­Vie

Bio­haven had a rough start to the year with fail­ing da­ta in Alzheimer’s that sent in­vestor in­ter­est spin­ning out. But the drug­mak­er still had a lot of rea­son to be­lieve in CGRP mi­graine med Nurtec de­spite a big chal­lenge from Ab­b­Vie — and now that be­lief is con­tin­u­ing to pay off.

The FDA on Thurs­day ap­proved Bio­haven’s CGRP drug Nurtec ODT as a pre­ven­ta­tive treat­ment for mi­graine, mak­ing the drug the first and on­ly op­tion for both acute mi­graine care and pre­ven­tion, the drug­mak­er said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER